Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

Lee, Michelle T.; Mahtta, Dhruv; Dlouhy, Louis; Shahab, Hunaina; Al Rifai, Mahmoud; Virani, Salim S.

doi:10.1007/s11883-021-00975-8

Record: found
Abstract: not found
Article: not found

Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

Author(s): Michelle T. Lee , Dhruv Mahtta , Louis Dlouhy , Hunaina Shahab , Mahmoud Al Rifai , Salim S. Virani

Publication date (Electronic): October 14 2021

Journal: Current Atherosclerosis Reports

Publisher: Springer Science and Business Media LLC

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 29

Record: found
Abstract: found
Article: not found

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E Inzucchi … (2020)

In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.

0 comments Cited 2025 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Juhani Knuuti, William Wijns, Antti Saraste … (2019)

0 comments Cited 1887 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker, Javed Butler, Gerasimos Filippatos … (2022)

Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain.